How Jill Lepore Discovered the Early Days of Data Mining for Public Manipulation – Observer

In the final weeks leading up the presidential election, one tendency would be to avoid all media related to politics. While older generations enjoyed morning and evening papers or television network news, todays preferred information platforms such as Twitter and Facebook inherently overwhelm the user with an excess of content that drives one to addiction or retreat. Is it possible to develop an ability to digest the news with some distance?

Having found myself reaching news saturation recently, I picked up Jill Lepores National Book Award longlisted nonfiction bookIf Then to think around these issues without submitting myself to constant news alerts. The book concentrates on the origins and impact of Simulmatics Corporation, a long forgotten company. Founded in 1959, Simulmatics was the brainchild of a flimflam man named Ed Greenfield whose false academic pedigree would have been sniffed out in minutes today. A white liberal, Greenfield hoped to bring his dream of a people machine to aid presidential politics. This was the time of bigger and better computer engineering as well as emerging fields of behavioral science.

Subscribe to Observers Arts Newsletter

Greenfield was an ideas man and needed others to execute his vision. He found a partner in a political scientist named Ithiel de Sola Pool. Together they embarked upon work that began with a successful involvement with John F. Kennedys 1960 presidential campaign and ended in Saigon with a doomed project aiding the American Department of Defense. Drawing from collected data, they utilized computer programming in order to predict outcomes based on if then questions. Take a look at social networking sites as well as Amazon, Google, or Cambridge Analytica and youll find their original blueprints in Simulmatics. For a company that only existed for just over a decade, what it set into motion by harnessing rapidly evolving technology and a commitment to nascent behavioral science was profound.

But it begs the question, how did Lepore connect the dots? In correspondence with the Observer via email, Lepore notes, Most of the books Ive written began in an archive. I find something, and then I get curious, so I look some more, and then I feel a strange compulsion to write about what Ive found. Her curiosity has led to books on the history of Wonder Woman, Benjamin Franklins sister Jane Franklin, as well as a study of slavery in 18th century Manhattan. This book began in the Ithiel de Sola Pool Papers at MIT. The collection is about two hundred boxes, mostly unprocessed, which is both a pain (because its hard to find things in an unprocessed collection) and fun (because when you find stuff you can be pretty sure no one else has found them before you).

This enthusiasm for detail and discovery is what transforms material that some would have considered dry fact into a vibrant narrative. Personal lives surface, certainly, but its more that Lepore has a steady sense of when to bring in cultural anchors such as Eugene Burdick, the political scientist who became a bestselling novelist, in addition to the domestic disputes such as the unstable marriages that plagued the company men.

And it was largely men who dominated this field. Over the course of reading the book, the lack of women in the proverbial room became uncomfortable and then claustrophobic. One could say this was another time, but it doesnt take away from the fact that behavioral science came into popularity during a time in which, culturally speaking, working women were discouraged to do more than execute programming tasks or serve as secretaries.

Lepore interestingly considers the wife of Bill McPhee, a mathematical sociologist recruited by Greenfield to work on a computer that would simulate voting behavior. Minnow Emery McPhee came from a family of accomplished women. Her mother attended Bryn Mawr College and her aunt was a professor of childhood development. Marriage to Bill derailed Minnows hopes of pursuing a career similar to her aunt. After mentioning another data collector, Betty Friedan, whose landmark book The Feminine Mystique originated in a set of interviews conducted with her Smith College classmates, Lepore notes that Minnow McPhee was all too aware of the crisis Friedan observed. However, Lepore goes further, stating in the book, There was a bigger problem, too. And it didnt have a name either. It had to do with knowledge itself. In the 1950s, when womens work was not work, womens knowledge was not knowledge. This had a disastrous effect on the two new fields of knowledge that this era produced: behavioral science and artificial intelligence.

Its unsurprising that these fields excluded women from the start, but it speaks to the ingrained arrogance that dominates the tech industry today. With great subtlety, Lepore raises these issues in the book with direct, but not incendiary, intention. Again, her commitment to archival work proves important. I was so grateful to have access to an incredibly rich archive of Minnow McPhees letters, which her granddaughter has lovingly collected and transcribed and annotated, she told Observer. It was just incredible. So often its so difficult to tell those domestic stories. It would be far too easy to let these histories slide into the melodrama of Mad Men. Lepores tight grip of pacing keeps these narratives tethered to the themes and actions at the center of the book.

She continues, I was also able to interview many of the children of the Simulmatics scientists, which was wonderful. [But it was] Minnow McPhees correspondence, in particular, that allowed me to help the reader gain a view of this world as it was lived by women and children, not as it was imagined by behavioral and computer scientists. The very sad and troubling irony [is that] these men were trying to build machines and create an artificial intelligence to understand and predict human behavior when they were ignoring and failing to understand their wives and children. When asked if she felt this exclusion continues today, Lepore affirms, Yes, its absolutely, entirely still with us.

Not only does Lepore touch upon the exclusion of women from workspaces, she also explores the ways in which this emerging technology crossed paths with the civil rights movement and anti-war movements of the moment. Desperate to keep his company afloat, Greenfield and Pool took Simulmatics to Vietnam in an equally doomed effort to read and then change the hearts and minds of the Vietnamese. This association with the American Department of Defense haunted Pool for the remainder of his career, despite his oracle work predicting the rise of social networks and the role of the Internet. These flawed men clung to emotional blind spots that prevented their operation from adapting in a way that would offer a more complete study of the subjects they hoped to fully understand.

At the close of the book, Lepore quotes the Google and Uber car designer Anthony Levandowski who in 2018 discredits the study of history. What already happened doesnt matter, he says dismissively. You dont need to know history to build on what they made. In technology, all that matters is tomorrow. Like any good historian, Lepore smells the lie in that statement and adds, The invention of the future has a history, decades old, dilapidated. Simulmatics is a cautionary tale, a timeworn fable, a story of yesterday. Because tomorrow is not all that matters.

Its reassuring to see Lepores context, but so is the manner in which she exposes the bloated words of snake oil salesmen such as this. When asked if Lepore felt that the industry would become subject to government regulation, she responded, Oh yes, regulation of this industry and even dismantlement of many of these companies is inevitable. Itll take time. But it will happen. If Then is an unnerving book that chronicles the birth of modern media and data manipulation. This prescient book is a warning for emerging behavioral studies and big technology. Lepore underscores the fact that history keeps the score.

Continued here:
How Jill Lepore Discovered the Early Days of Data Mining for Public Manipulation - Observer

Gravyty Launches Gravyty Guard the First Data Security Solution Built to Protect Donor Data at Nonprofit Organizations – PRNewswire

BOSTON, Oct. 6, 2020 /PRNewswire/ --Gravyty, the market-defining leader of artificial intelligence (AI) for Social Good, today announced Gravyty Guard, the first data security technology focused on the human layer of security and specifically designed to protect the most sensitive donor data at nonprofit organizations from intentional and unintentional data breaches. The announcement comes in direct response to the worst year for nonprofit data security, with thousands of nonprofit organizations announcing data breaches and millions of donor data records compromised. Gravyty Guard protects nonprofit organizations and their well-intentioned employees from unintentional and malicious data breaches and provides the first solution to secure organizations' most sensitive data.

Over the past six months, remote work has redefined how workforces' access and share donor data, creating new and alarming security vulnerabilities for nonprofit organizations, particularly through well-intentioned employees who have authorized access to their organization's data. In fact, 85%of data breaches occur as a result of inadvertent actions. As data sets grow exponentially and organizations become more data-driven, these vulnerabilities are only projected to get worse. The most prominent risks now become well-intentioned employees who make mistakes with their organizations' data.

"Nonprofit organizations find themselves in the crosshairs of being data-driven and needing to protect their most sensitive donor data. In the past, we've relied on policy to provide security assurances, but 2020 has proven that we need more, and it has to start at the most vulnerable level -- the human layer," explained Adam Martel, co-founder and CEO, Gravyty. "With Gravyty's deep understanding of the nonprofit sector and human behavior in advancement, we realized that we could expand our AI platform so nonprofits can address the security challenge that will define this decade, protecting against fraud and data breaches with world-class technology."

By understanding human behaviors unique to the nonprofit fundraising space, Gravyty uses advanced technologies to train models, deploy proactive alerts, and provide detailed, flexible reporting to protect employees from being the source -- maliciously or accidentally -- of the next donor data security breach. Known as human-layer security, the technologies behind Gravyty Guard proactively alert fundraisers to potential data breaches and provide steps to remediate data risks. These protections include threats such as:

Email InfiltrationPhishing, spear phishing, and other email infiltration attacks attempt to trick humans into scenarios that allow hackers to extract sensitive donor data through ransomware, trojan malware, and other methods. An estimated 135 million of these attacks are attempted every day. Historically focused on the for-profit sector, the nonprofit sector has only recently become a target for bad actors. Gravyty Guard is flexible, configuring to the specific needs of any organization to alert and protect fundraisers from these attacks.

Data ExfiltrationExfiltration happens when employees use email, text messages, messaging apps, thumb drives, cloud apps, and other vehicles to transfer data to places it should never be, without authorization. The most common data exfiltration occurs when an employee forwards a work email to their personal account. 75% of IT leaders say employees intentionally put an organization's data at risk through exfiltration methods. Gravyty Guard allows nonprofit organizations to select compliance frameworks that apply to their business -- GDPR, CCPA, HIPAA, or otherwise -- and alerts managers when a fundraiser is about to create a vulnerability.

Anomalous BehaviorIT security is often highly effective at monitoring networks for abnormal traffic. However, we can't say the same about tracking abnormalities in human behavior. More than 70% of people have mistakenly sent personally identifiable information (PII) or business-sensitive data to the wrong email recipient, creating a data breach. The source of these breaches could be as small as trusting auto-suggest to fill in an email address or a typo. Gravyty Guard uses AI to monitor security anomalies at the human-layer, alerting fundraisers when something doesn't line up about the data within their message and the recipients to whom it's being sent.

"The last 30 years in security have been defined by protecting networks and devices. Now, bad actors have turned their attention to new vulnerabilities -- an organization's employees," said Rich Palmer, co-founder and CTO, Gravyty. "As the leader in AI technology for the nonprofit sector, addressing human-layer security is a natural progression for Gravyty because frontline fundraisers access sensitive donor data every day. We'll empower nonprofit organizations to ensure their employees don't make mistakes that cause donor data breaches."

Gravyty Guard is available immediately in beta and will be released in full to the entire nonprofit community in early 2021. The three best ways to learn more about Gravyty Guard are to:

About GravytyGravyty is the market-defining leader of artificial intelligence (AI) for Social Good. We exist so the nonprofit sector can evolve to transform what's possible through philanthropy. Our AI platform focuses on fundraiser efficiency and donor data security. Gravyty automates the most time-consuming processes that get in the way of fundraisers doing the work they love -- developing and cultivating relationships with donors. By empowering fundraisers to efficiently personalize outreach, build new relationships faster, steward and deepen existing relationships, and keep donor data safe, our customers expand their workforces without making new hires and increase revenue from giving. Visit http://www.gravyty.com to learn more.

Media Contact:Kevin Leahy833.472.8989[emailprotected]

SOURCE Gravyty

Gravyty | Fundraising software | Community engagement software

Read the original:
Gravyty Launches Gravyty Guard the First Data Security Solution Built to Protect Donor Data at Nonprofit Organizations - PRNewswire

SKYMINT BRANDS — Formerly Green Peak Innovations — Joins Forces With DNA Genetics To Bring The World’s Most Globally Awarded Flower Strains To…

"SKYMINT BRANDS and DNA Genetics share a similar brand ethos in that we are both on a mission to provide cannabis enthusiasts with the highest quality flower possible," says SKYMINT BRANDSCEO Jeff Radway. "All flower is not created equal, and DNA Genetics knows this better than anyone else, which is why our SKYMINT X DNA GENETICS collaboration truly sets a high bar in Michigan."

Launching tomorrow, October 9, at all seven recreational SKYMINT locations throughout the state of Michigan, as well as select retail partners, SKYMINT X DNA GENETICS features a premium collection of seven of the most globally awarded and sought-after flower strains, including Bakers Delight and Ztrawberriez, as well as:

Clementine Flower $701st Place, High Times Cannabis Cup 20191st Place, 710 Degree Cup

Kosher Kush Flower $701st Place, High Times Cannabis Cup 2010Top 10 Strain of the Year, High Times Cannabis Cup 20111st Place Milano Secret Cup 2018People's Choice, Cannabis Cup Brazil 2016

LA Confidential Flower $701st Place, High Times Cannabis Cup 2008

Chocolope Flower $70TEN 1st Place Awards, including 1st Place, High Times Cannabis Cup 2010

Strawberry Banana Flower $701st Judges Choice, Cannabis Cup Brazil 20161st Place, High Times Socal Cup 2016

Certified as to provenance by DNA GENETICS, each seed was hand-chosen by founders Don Morris and Aaron Yarkoni and farmed to perfection by SKYMINT cultivators. Two additional strains, Gelato Sorbet and Lemon Skunk, are still to be released by year's end, as are .7 gram pre-rolls.

"Each time we explore a potential collaboration, we look for the best possible partner in each market and SKYMINT BRANDS is that partner for Michigan," says Don Morris, Co-Founder of DNA Genetics. "The extreme level of care, commitment, and innovation that SKYMINT BRANDS infuses into its cultivation and product brands inspires great confidence."

The SKYMINT X DNA GENETICS collaboration marks a new moment in Michigan's progressive cannabis market. Recreational cannabis only came online last December, and Michigan's industry has scaled rapidly, with SKYMINT a leader in that growth, establishing 10 dispensaries in seven months with two more planned to open this year.

Since its inception in 2018, SKYMINT BRANDS has dedicated itself to creating and curating premium-crafted cannabis brands, hand-grown with expert care to power a portfolio of the finest cannabis brands available for daily wellness, healing, and recreational enjoyment. Joining SKYMINT X DNA GENETICS under the SKYMINT BRANDS umbrella are SKYMINT, North Cannabis, Jolly Edibles, and the Two Joints brand, which benefits the Last Prisoner Project.

"There's good cannabis, there's better cannabis, and then there's SKYMINT X DNA GENETICS," says Laurie Gregory, Chief Brand and Product Officer at SKYMINT BRANDS. "While all of our SKYMINT BRANDS are premium, the SKYMINT X DNA GENETICS collection delivers superior genetics, flavor, and effects for a consistent, elevated experience that's unparalleled. SKYMINT X DNA GENETICS is literally the best cannabis that our state has to offer, marking a high point for our brand and for Michigan."

Adds Radway, "SKYMINT X DNA GENETICS embodies the three pillars that inspire our work at SKYMINT BRANDS: to elevate cannabis in Michigan and beyond; to cultivate stellar, premium brands; and to leverage our resources and position within the industry to change the world and our communities for the better."

The SKYMINT X DNA GENETICS launch coincides with the company's recent transition from its founding name - Green Peak Innovations - to SKYMINT BRANDS.

"SKYMINT BRANDS reflects our belief in the exponential potential of cannabis to revolutionize lives and inspire people everywhere to feel better, live better, do better, and create better. This collaboration is a perfect example of that aim. With access to the world's best cannabis, the SKY's the limit," says Gregory.

PRESS KIT

About SKYMINT BRANDSBeginning operations in Fall 2018, Skymint (formerly known as Green Peak Innovations) is Michigan's leading vertically integrated cannabis company and the state's largest medical and recreational license holder. With two state-of-the-art indoor grow facilities, the company cultivates, processes, markets, distributes and sells a full range of branded cannabis products, including SKYMINT, North Cannabis, Jolly Edibles, the Two Joints brand, which benefits the Last Prisoner Project, and SKYMINT X DNA GENETICS. Just as SKYMINT treats its plants like people - tending to and caring for them by hand, and even playing them music - each and every product is handcrafted to ensure the safest, cleanest, highest quality products at the best value. SKYMINT products can be found at the company's SKYMINT provisioning centers and via retailers around Michigan through a robust wholesale network. As purveyors of premium-crafted cannabis, SKYMINT has developed a portfolio of the finest cannabis brands available for daily wellness, healing, or just getting high on life. SKYMINT inspires people everywhere to feel better, live better and do better. Learn more: http://www.skymint.com/dna-x-skymint/

Press Contact: Holly Aubry / HUMAN NATURE / [emailprotected] / 646.943.0541

About OG DNA Genetics Inc.DNA was rooted in Los Angeles and founded in Amsterdam in 2004 by Don Morris and Aaron Yarkoni. Over the last decade, the Company has built and curated a seasoned genetic library and developed proven standard operating procedures for genetic selection, breeding, and cultivation. In a world that is increasingly opening up to commercial cannabis activity, DNA is positioned to become the first, truly geographically-diversified company with multiple partnerships with top-licensed producers and brands that have built their companies and global presence utilizing the "Powered by DNA" model.

For more information, please visit http://www.dnagenetics.com

Press Contact: Rezwan Khan, President of DNA Genetics at [emailprotected]

SOURCE SKYMINT BRANDS

Read this article:
SKYMINT BRANDS -- Formerly Green Peak Innovations -- Joins Forces With DNA Genetics To Bring The World's Most Globally Awarded Flower Strains To...

Excess genetic exchanges impede the segregation of chromosomes into eggs – News-Medical.net

Reviewed by Emily Henderson, B.Sc.Oct 8 2020

The exchange of DNA between chromosomes during the early formation of sperm and egg cells normally is limited to assure fertility.

But when there are too many of these genetic exchanges, called crossover events, the segregation of chromosomes into eggs is flawed, biologists have learned in a project done across three labs at the University of Oregon and Northwestern University.

In a paper published online Sept. 4 in the journal PLOS Genetics, researchers documented how the disruptions, as seen in basic research with microscopic roundworms (Caenorhabditis elegans), lead to a range of meiotic defects as the chromosomes are subjected to improper spindle forces.

Inaccurate chromosome segregation in humans is associated with Down syndrome and miscarriages. Such segregation defects as seen in the research can result in increased infertility, said UO biologist Diana E. Libuda, the study's principal investigator.

Over the past century, research has focused on making sure enough crossovers are made during sperm and egg development. It was known that developing sperm and eggs had ways to make sure that not too many crossovers are made, but it was unclear why."

Diana E. Libuda, Professor in the UO's Department of Biology and Institute of Molecular Biology

The research team identified two mechanisms that help counteract defects triggered by excess crossover activity in developing eggs and, thus, assist the coordination of the process that helps assure genomic integrity in new generations.

Libuda had reported in the Oct. 9, 2013, issue of Nature the discovery of a mechanism that inhibits the overproduction of crossovers in roundworms. However, Libuda said, it was not possible at that time to study the downstream effects in cases where too many crossovers did occur. Since then, her lab developed a way to generate extra crossovers on a single chromosome.

That ability led to a National Institutes of Health-funded collaboration with Sadie Wignall of Northwestern University, an expert on high-resolution imaging of structures involved in segregation of chromosomes into developing eggs. What Wignall found led Libuda back to Bruce Bowerman's UO lab to take a look at chromosome segregation in live developing eggs.

"Overall, it was a great joining of scientific strengths to take a multipronged approach to answer this important question," Libuda said.

The research provides fundamental insights that can guide research in other organisms to better understand the mechanisms and, eventually, lead to potential clinical applications.

"The same proteins that we are studying in C. elegans are also in humans," Libuda said. "In fact, most proteins required for fertility are used across organisms that include yeast, fruit flies, nematodes, zebrafish, mice and humans. Research using these microscopic worms has been shown in numerous contexts to have relevance in human health. "

Source:

Journal reference:

Hollis, J.A., et al. (2020) Excess crossovers impede faithful meiotic chromosome segregation in C. elegans. PLOS Genetics. doi.org/10.1371/journal.pgen.1009001.

See the original post:
Excess genetic exchanges impede the segregation of chromosomes into eggs - News-Medical.net

Seattle Genetics? Not anymore. The biotech has shortened its name to Seagen to illustrate global expansion – Endpoints News

Would a Seattle Genetics by any other name smell as sweet? Were about to find out.

The biotech announced Thursday its changing its name to Seagen, capping off whats been a 12-month period in which it closed a $4.5 billion deal with Merck and saw two drugs get FDA approval. Seagen is also keeping the same Wall Street ticker $SGEN.

CEO Clay Siegall said the company made the change to represent its expanding global operations.

Our goal is to help cancer patients around the world, Siegall said. It is, to us, better to be reflected as a biotechnology company that makes cancer products for the globe, and as weve expanded it makes sense.

Cancer patients dont have boundaries or borders, he added.

On top of all that, Seagen presented positive Phase II data at ESMO just a few weeks ago. The companys experimental drug tisotumab vedotin, an antibody-drug conjugate, showed an average response lasting 8.3 months and an objective response rate of 24% in 101 patients with recurrent or metastatic cervical cancer.

Though it was a single-arm trial, Seagen compared the results to data suggesting existing therapies typically have a response rate of less than 15% and patients survive for 6 to 9.4 months.

So why change things up now? Siegall said that the company had already been calling itself Seagen internally and internationally, pointing to its seagen.com email addresses in use since inception and overseas affiliates such as Seagen France. By shortening the name, Siegall said, Seagen not only makes things less cumbersome but also lets the company stay attached to its Seattle roots.

We definitely are proud of our Pacific Northwest roots; Seattle is known as the Emerald City and thats why green is in our logo, Siegall said. While we are retaining our strong roots and the S-E-A in our name, this expansion really makes it, we feel, a more appropriate name for a global company.

Siegall likened it somewhat to the delivery service Federal Express shrinking its name to FedEx in the mid-1990s. Though the two companies have no semblance of comparison, Siegall said, Seagen is adopting a nickname thats been the unofficial moniker for years and keeping the same colors in its logo.

At the end of the day though, this rebranding wont change anything about Seagens business. Siegall talked at length about how the new name signifies Seagen is an international company, but emphasized that its cancer products remain its true brand.

This is not something where we are trying to overstate our name change as something more than what it is, Siegall said. This is a minor change, but something that we think is good going forward and very productive. I dont think anyone should view this as Seattle Genetics is doing something different.

Originally posted here:
Seattle Genetics? Not anymore. The biotech has shortened its name to Seagen to illustrate global expansion - Endpoints News

Evenings with Genetics discusses connection between cancer and genetics – Baylor College of Medicine News

Content

Does cancer run in families? A genetic counselor from Baylor College of Medicine will answer that question and more about cancer genetics during the Evenings with Genetics virtual seminar on Tuesday, Oct. 13, at 7 p.m.

During the hourlong webinar, Tanya Eble, genetic counselor and assistant professor of molecular and human genetics at Baylor, will discuss cancer red flags to look for in your personal or family history, what to expect at a cancer genetics evaluation as well as gene tests for hereditary breast and colon cancer syndromes. Judy Karonika of Judy's Mission, a nonprofit aimed at increasing awareness, education and prevention of ovarian cancer, and patient advocate Nancy Khan will also speak.

Evenings with Genetics is a regular speaker series hosted by Baylor College of Medicine and Texas Childrens Hospital that offers the most current information on care and research advances for many genetic conditions. The seminars provide an opportunity for patients in the genetics community to interact with other families experiencing similar situations.

The program is free and open to the public, but registration is required. A Zoom link will be sent to all registered participants the day before the seminar. For more information, call 713-798-8407 or visit the event registration page.

More:
Evenings with Genetics discusses connection between cancer and genetics - Baylor College of Medicine News

Coronavirus antibodies last at least three months after infection, U of T study finds – News@UofT

Coronavirus antibodies can last at least three months after a person becomes infected with the virus that causes COVID-19, according to a study published in Science Immunology.

Researchers from the University of Toronto and the Lunenfeld-Tanenbaum Research Instituteat Sinai Health used both saliva and blood samples from COVID-19 patients to measure and compare antibody levels for over three months post-symptom onset.

They found that antibodies of the IgG class that bind to the SARS-CoV-2 spike protein are detectable for at least 115 days, representing the longest time interval measured. The study is also the first to show these antibodies can also be detected in the saliva.

Our study shows that IgG antibodies against the spike protein of the virus are relatively durable in both blood and saliva, said Jennifer Gommerman, professor of immunology in U of Ts Temerty Faculty of Medicine and leader of the saliva testing effort.

Our study suggests saliva may serve as an alternative for antibody testing. While saliva is not as sensitive as serum, it is easy to collect.

The saliva assay was developed at U of Twhile a team at Lunenfeld-Tanenbaum, led by senior investigator Anne-Claude Gingras, who is also a professor of molecular genetics at U of T, executed the serum assay.

The LTRI platform for detection of antibodies in serum, or blood, is incredibly robust and well suited for assessing the prevalence of infection within the community, said Gingras. This is another tool that can help us better understand and even overcome this virus.

Anne-Claude Gingras, a professor of molecular genetics at U of T, led a team at theLunenfeld-Tanenbaum Research Institute that executed the serum assay for the study (photo courtesy of Mount Sinai Hospital)

Most people who recover from COVID-19 develop immune agents in their blood called antibodies that are specific to the virus. These antibodies are useful in indicating who has been infected, regardless of whether they had symptoms or not.

A large team of scientists collaborated on the study, including Allison McGeer and Mario Ostrowski, who provided access to the paired saliva and serum samples from dozens of patients for the study.

McGeer is a professor of laboratory medicine and pathobiology at U of T, a senior clinician scientistat Lunenfeld-Tanenbaum and principal investigator of the Toronto Invasive Bacterial Diseases Network. Ostrowski is a professor of medicine, immunology, and laboratory medicine and pathobiology at U of Tand a scientist at St. Michaels Hospital, Unity Health Toronto.

The study was co-led by U of T graduate students Baweleta Isho, Kento Abe, Michelle Zuo and Alainna Jamal. James Rini, a professor of biochemistry and molecular genetics at U of T, and Yves Durocher from the National Research Council of Canada, provided key protein reagents for the saliva studies.

The durability of the antibody response to SARS-CoV-2 has been debated in recent months. An earlier study published in Nature Medicine suggested the antibodies can disappear after two months for some individuals who had the virus but did not experience symptoms.

This study led by the Toronto team is in agreement with findings from leading immunologists in the U.S. in describing the antibody response as longer lasting.

While the team admits there is a lot they still dont know about antibody responses to SARS-CoV-2 infection, including how long the antibodies last beyond this period or what protection they afford against re-infection, the research could have broader implications in the development of an effective vaccine.

This study suggests that if a vaccine is properly designed, it has the potential to induce a durable antibody response that can help protect the vaccinated person against the virus that causes COVID-19, Gommerman said.

The researchwas supported by an Ontario Together grant and funding from the Canadian Institutes of Health Research. Funding for the development of the assays in the Gingras lab was provided through donations bythe Royal Bank of Canada, Questcap and the Krembil Foundation.

Read the original:
Coronavirus antibodies last at least three months after infection, U of T study finds - News@UofT

Kirby Institute awarded over $7m for HIV, hepatitis C and COVID-19 immunology research – UNSW Newsroom

A combined $7.55 million has been awarded to two immunology projects at the Kirby Institute at UNSW Sydney via the Australian governments Medical Research Future Fund (MRFF) scheme.

Through the Pathogen Genomics initiative, $6.6 million has been awarded to a large collaborative, multidisciplinary team led by Kirby Institute Director Professor Anthony Kelleher, to investigate the effectiveness of HIV and hepatitis C public health initiatives using viral genomics.

The significant project will see the establishment of national networks, governance and infrastructure to enable enhanced collection of public health metadata and viral sequence for HIV and hepatitis C across the country.

Using the latest technology and innovation in molecular epidemiology, this research will facilitate the rapid genomic analysis of virus diversity and transmissions networks for HIV and hepatitis C infection in Australia, in near real-time, says Prof. Kelleher.

Very importantly, these systems will be developed in partnership with peak community bodies to ensure patient privacy is a primary consideration, and that any systems developed are acceptable to affected communities.

The project, which is the first of its kind in Australia, will deploy high-level viral sequencing and bioinformatic systems into existing clinical and public health networks. This will enable the identification of trends in virus spread and new infections and enhance the already highly effective public health response to these increasingly dispersed epidemics.

The ability to conduct molecular epidemiological analyses in near real-time will improve Australias already world-class response to HIV and hepatitis C, by allowing us to finely map the effectiveness of particular public health strategies, and to optimise our efforts by identifying areas where more targeted campaigns are necessary. We hope this model will allow more effective use of public health investments and allow targeting to areas of greatest need, says Prof. Kelleher.

This ambitious research program will be conducted in close collaboration with colleagues within the Public Health Laboratory Network (PHLN), jurisdictional public health units, industry and multiple partners from community.

The current COVID-19 pandemic has shown the importance and effectiveness of a coordinated nation-wide system for the collection, analysis and interpretation of pathogen transmission. We hope this project will fill the gaps of current prevention strategies, enabling a rapid and effective public health response with the aim of virtually eliminating these infections in Australia," says Prof. Kelleher.

A grant of $995,500 has been awarded to a team from the Kirby Institute, UNSW, Lifeblood, the Garvan Institute and St Vincents Centre for Applied clinical research. Led by Associate Professor Stuart Turville, the research will explore the bodys immune response to COVID-19.

People who become infected with SARS-CoV-2 have a range of immune responses. Some clear the virus with limited involvement of antibodies and other forms of longer term acquired immunity, says A/Prof. Turville.

Other patients mount a longer, sustained response, with secretion of high levels of antibodies and mobilisation of T cells, a key component of cellular immunity. The latter are produced to combat the spread of the virus in patients that may have symptoms of greater disease severity.

This project will analyse patient antibodies and cells over time. Many assays have already been developed from scratch in the Kirby Institutes Glendonbrook Laboratories to map the COVID-19 immune response.

A/Prof. Turville says it is critical to understand the immune response in great detail, in order to inform public health measures, treatment and vaccine delivery.

By studying the immune response in a range of patients, we will be able to understand the overall risk of re-infection in the community and if the immune response contributes to any ongoing symptoms following COVID-19 infection, he says.

The research will identify patients with potent immune responses to the virus, and will investigate how and why certain individuals have mounted a greater immune response. This information will be used to understand natural immunity to the virus and for immunotherapy and vaccine development.

A key aspect of the study will combine highly sensitive and novel methodology to follow two unique patient cohorts. The first is through a collaborative partnership with Australian Red Cross Lifeblood, which coordinates thousands of blood donors nationwide who have recovered from COVID-19. The second is a Sydney-based cohort called ADAPT, headed by the Kirby Institutes Associate Professor Gail Mathews at St Vincents Hospital. Combining both cohorts, the study will not only give us a snapshot of the overall immune responses across Australia, but also how this relates to disease severity and ongoing COVID-19-related symptoms.

The need for knowledge of the immune response, along with the right biomedical tools, is paramount in building the arsenal to stop the spread of COVID-19, and in the short term, generating immunotherapeutics to save peoples lives, says A/Prof. Turville.

Professor Tony Butler, from the School of Population Health at UNSW Medicine, was awarded $232,159 to investigate the mental health needs of the Australian population during COVID-19. Prof. Butlers project will use an automated method, including text mining and data linkage, to process police records over the past four years and investigate whether there have been any increases in mental illnesses both before and during the COVID-19 crisis.

Pro Vice-Chancellor Research Professor Ana Deletic congratulates all of the grant recipients.

These three grants are a testament to the fact that UNSWs high performing research in virology is among the best in Australia and we remain focused on delivering impactful outcomes in medical research, Prof. Deletic says.

It is pleasing that in 2020 we have been awarded over $90 million in MRFF grants which is becoming one of our largest funding sources.

See more here:
Kirby Institute awarded over $7m for HIV, hepatitis C and COVID-19 immunology research - UNSW Newsroom

HKUMed develops a novel therapeutic approach against Epstein-Barr virus-associated tumours by using exosomes derived from V2-T cells – India Education…

A research team at LKS Faculty of Medicine, The University of Hong Kong (HKUMed) discovered that exosomes derived from V2-T cells (V2-T-Exos) can effectively control Epstein-Barr virus-associated tumours and induce T-cell anti-tumour immunity. The novel findings of V2-T-Exos provide insights into new therapeutic approach for Epstein-Barr virus (EBV)-associated tumours. The ground-breaking findings have been published in the leading academic journal, Science Translational Medicine. [Link to the publication]

BackgroundEBV infects about 95% of the human population and causes more than 200,000 cases of cancer each year and that around 2% of all cancer deaths are due to EBV-attributable malignancies. EBV-associated tumours include Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, gastric tumour and post-transplant lymphoproliferative disease, etc. Current treatment options for EBV-associated tumours are limited with considerably unwanted off-target toxicities and incomplete effectiveness for relapsed or refractory disease. V2-T cells are innate-like T cells with anti-tumour potentials against EBV-associated tumours. Unfortunately, its clinical translation is limited because V2-T cells from some cancer patients are difficult to be expanded. Exosomes are endosome-originated small extracellular vesicles that mediate intercellular communication. Compared with cell-based therapy, cell-free exosomes have advantages with higher safety, easier storage, and lower costs. However, the anti-tumour activity of exosomes derived from V2-T cells (V2-T-Exos) remains unknown.

Research findingsHerein, the team found that V2-T-Exos contained death-inducing ligands (FasL and TRAIL) and immunostimulatory molecules (CD80, CD86, MHC class I and II). V2-T-Exos targeted and efficiently killed EBV-associated tumour cells through FasL and TRAIL pathways and promoted EBV antigen-specific CD4 and CD8 T cell expansion. Administration of V2-T-Exos effectively controlled EBV-associated tumours in immunodeficient and humanized mice. Because expanding V2-T cells and preparing autologous V2-T-Exos from cancer patients ex vivo in large scale is challenging, the team further explored the anti-tumour activity of allogeneic V2-T-Exos in humanized mouse cancer models. Interestingly, the team found that allogeneic V2-T-Exos had more effective anti-tumour activity than autologous V2-T-Exos in humanized mice; the allogeneic V2-T-Exos increased the infiltration of T cells into tumour tissues and induced more robust CD4 and CD8 T cells-mediated anti-tumour immunity. Compared with exosomes derived from NK cells with direct cytotoxic anti-tumour activity or dendritic cells that induced T-cell anti-tumour responses, V2-T-Exos have dual anti-tumour activities by directly killing tumour cells and indirectly inducing T cells-mediated anti-tumour responses, thus resulting in more effective control of EBV-associated tumours.

Our study provides the first evidence about the anti-tumour activities of V2-T-Exos against EBV-associated tumours. These exosomes could effectively control EBV-associated cancers in multiple mouse models. More importantly, allogeneic V2-T-Exos had higher therapeutic efficacy than autologous V2-T-Exos to control EBV-associated tumours. Therefore, the V2-T-Exos prepared from healthy donors can be used to treat patients with EBV-associated tumours, which is highly beneficial to the clinical application of this novel approach, said Professor Tu Wen-wei, Antony and Nina Chan professor in Paediatric Immunology, Department of Paediatrics and Adolescent Medicine, HKUMed, who led the research.

Significance of the studyThe findings of the study have significant implications in cancer immunotherapy. Firstly, the identification that V2-T-Exos has potent immunostimulatory property suggests that they could be designed as a cancer vaccine by serving as immune adjuvant and delivering immunogens. Secondly, the V2-T-Exos has advantages over other exosome-based therapies (e.g. NK-Exos and DC-Exos) by displaying dual anti-tumour activities and are easier in preparation. Thirdly, the results that allogeneic V2-T-Exos have higher anti-tumour efficacies than autologous V2-T-Exos can greatly enhance the clinical feasibility of V2-T-Exos, because the preparation of allogeneic exosomes does not require personalized procedures and is easier in quality control, standardization and centralization for clinical application.

About the research teamThe research was led by Professor Tu Wen-wei, Antony and Nina Chan Professor in Paediatric Immunology, Department of Paediatrics and Adolescent Medicine, HKUMed. Dr Wang Xi-wei, post-doctoral fellow of Professor Tus team, is the first author. Other researchers include Dr Zheng Xiang, post-doctoral fellow of Professor Tus team; Dr Liu Yin-ping, Research Officer in Department of Paediatrics and Adolescent Medicine, HKUMed; Ms Huang Chun-yu, PhD student of Professor Tu; Dr Pei Yu-jun, post-doctoral fellow of Professor Tus team; Dr Pamela Lee Pui-wah, Clinical Associate Professor, Department of Paediatrics and Adolescent Medicine and Assistant Dean (Clinical Curriculum), HKUMed; Professor Godfrey Chan Chi-fung, Tsao Yen-Chow Professor in Paediatrics and Adolescent Medicine, Head and Clinical Professor of Paediatrics and Adolescent Medicine, HKUMed; Professor Lau Yu-lung, Doris Zimmern Professor in Community Child Health and Chair Professor of Paediatrics, Department of Paediatrics and Adolescent Medicine, HKUMed; Collaborators include Dr Wang Xia, post-doctoral fellow, Department of Pathology, HKUMed; Dr Helen Zhi, Director of Biostatistics and Clinical Research Methodology Unit, School of Public Health, HKUMed; Dr Wilfred Wong Hing-sang, Senior IT Manager, Department of Paediatrics and Adolescent Medicine, HKUMed. Professor Wei Hai-ming, Institute of Immunology, University of Science and Technology of China, Hefei, Anhui, Mainland China; Professor Irene Ng Oi-lin, Loke Yew Professor in Pathology, Director of State Key Laboratory of Liver Research (HKU), Chair of Pathology, HKUMed.

Collaborating institutions contributing to the research include the Institute of Immunology, University of Science and Technology of China, Hefei, Anhui, Mainland China.

This work was supported in part by General Research Fund (17122519, 17126317, 17115015, 17121214), Theme-based Research Scheme from the Research Grants Council (Project No. T11-705/14N), and The Area of Excellence Scheme (AoE/M-06/08) supported by the University Grants Committee, Government of the Hong Kong Special Administrative Region.

Originally posted here:
HKUMed develops a novel therapeutic approach against Epstein-Barr virus-associated tumours by using exosomes derived from V2-T cells - India Education...

Two Penn Med professors win total of $8 million in grants from National Institutes of Health – The Daily Pennsylvanian

The Perelman School of Medicine's Brian Litt (left) and Gregory Corder (right) were awarded Directors Awards from the National Institutes of Health.

The National Institutes of Health awarded its Director's Awards, which include a combined $8 million in research grants to two professors at Penns Perelman School of Medicine.

Brian Litt, a professor of neurology, neurosurgery, and bioengineering, and Gregory Corder, an assistant professor of neuroscience and psychiatry, are two of this year's 85 recipients, Penn Medicine News reported.

The awards are part of the NIH Common Fund's "High-Risk, High Reward Research Program," which aims to "fuel research endeavors that are more open-ended and could have a broader effect on scientific understanding than traditional research." Corder was awarded the New Innovator Award, receiving $2.4 million to investigate the mechanisms of chronic pain, and Litt was awarded the Pioneer Award for $5.6 million which will support his novel neurodevice research.

Litt is working to develop autonomous neurodevices, or "implanted machines that can question, record, and combine learning algorithms based on neurological signals and feedback to act and alter human behavior on the fly," Penn Medicine News reported.

For patients with epilepsy, the devices would predict and prevent seizures. In Parkinson's patients, implants would communicate with patients to improve mobility, reduce tremors, and enhance responsiveness.

Corder plans to use the grant to "identify which parts of the brain are important for pain perception and which circuits impact pain relief from opioids," Penn Medicine News reported.

In the wake of widespread opioid addiction that has increased over the past decade, this research can pave the way for effective pain-relief treatment without the addictive properties of opioids.

We currently have a limited understanding of the neural pathways in the brain that contribute to pain, which has been a significant barrier for treating pain efficiently, without negative side effects," Corder told Penn Medicine News. "But, if we can identify and understand these circuits, we can then try to rewrite the neural code of pain.

See the rest here:
Two Penn Med professors win total of $8 million in grants from National Institutes of Health - The Daily Pennsylvanian